Transcatheter versus Surgical Aortic Valve Replacement in High Risk Patients with Severe Aortic Stenosis: Results From

0
0
2534 days ago, 1009 views
PowerPoint PPT Presentation
Transcatheter versus Surgical Aortic Valve Supplanting in High Hazard Patients with Serious Aortic Stenosis: Results From The Accomplice Trial. Craig R. Smith, MD for the benefit of The Accomplice Trial Specialists. ACC 2011 | New Orleans | April 3, 2011.

Presentation Transcript

Slide 1

Transcatheter versus Surgical Aortic Valve Replacement in High Risk Patients with Severe Aortic Stenosis: Results From The PARTNER Trial Craig R. Smith, MD in the interest of The PARTNER Trial Investigators ACC 2011 | New Orleans | April 3, 2011

Slide 2

Presenter Disclosure Information for PARTNER at ACC April 3, 2011 Craig R. Smith, MD PARTNER Trial support (Edwards LifeSciences ) repays standard travel and different costs

Slide 3

Background Surgical aortic valve substitution (AVR) is the standard of look after treating patients with symptomatic aortic stenosis who are contender for operation. Despite the fact that transcatheter aortic valve substitution (TAVR) decreases mortality in patients who can't have AVR, there have been no randomized trials contrasting TAVR with AVR in patients who are at high-chance for operation.

Slide 4

Purpose To look at the wellbeing and adequacy of TAVR (either transfemoral or transapical ) to surgical AVR in high-hazard, operable patients with symptomatic, serious aortic stenosis .

Slide 5

PARTNER Study Design Symptomatic Severe Aortic Stenosis ASSESSMENT: High-Risk AVR Candidate 3,105 Total Patients Screened Total = 1,057 patients High Risk Inoperable N = 358 N = 699 2 Parallel Trials: Individually Powered ASSESSMENT: Transfemoral Access Yes No 1:1 Randomization Not In Study N = 179 N = 179 TF TAVR Standard Therapy VS Primary Endpoint: All-Cause Mortality Over Length of Trial (Superiority ) Co-Primary Endpoint: Composite of All-Cause Mortality and Repeat Hospitalization (Superiority)

Slide 6

Inoperable PARTNER Cohort Primary Endpoint: All-Cause Mortality HR [95% CI] = 0.54 [0.38, 0.78] P (log rank) < 0.0001 Standard Rx TAVI ∆ at 1 yr = 20.0% NNT = 5.0 pts 50.7% All-cause mortality (%) 30.7% Months Leon et al, NEJM 2010; 363:1597-1607

Slide 7

PARTNER Study Design Symptomatic Severe Aortic Stenosis ASSESSMENT: High-Risk AVR Candidate 3,105 Total Patients Screened Total = 1,057 patients Inoperable High Risk N = 358 N = 699 2 Parallel Trials: Individually Powered ASSESSMENT: Transfemoral Access ASSESSMENT: Transfemoral Access Yes No Transapical (TA) Transfemoral (TF) Yes No 1:1 Randomization 1:1 Randomization 1:1 Randomization Not In Study N = 244 N = 248 N = 104 N = 103 N = 179 N = 179 TF TAVR AVR TA TAVR AVR TF TAVR Standard Therapy VS Primary Endpoint: All-Cause Mortality Over Length of Trial (Superiority ) Co-Primary Endpoint: Composite of All-Cause Mortality and Repeat Hospitalization (Superiority) Primary Endpoint: All-Cause Mortality at 1 yr (Non-mediocrity)

Slide 8

Primary Endpoint All-cause mortality at one year Analysis by plan to-treat Event rates by Kaplan-Meier gauges Crossovers allowed just when allocated treatment unsuccessful All patients took after for ≥ one year

Slide 9

Other Important Endpoints (1) Safety: Neurologic occasions Prospective: Stroke and stroke in addition to TIA (all neuro occasions) Retrospective: Major stroke (changed Rankin Score ≥ 2 @ ≥ 30 days) Major vascular intricacies (VARC definition) Major dying (adjusted VARC definition) Repeat hospitalization New pacemakers and new-onset atrial fibrillation (ECG center lab) Procedural occasions (relegated treatment prematurely ended or changed over to AVR, different valves, and so forth.) Surgical difficulties (re-operation for dying, sternal disease, and so on.)

Slide 10

Other Important Endpoints (2) Clinical Effectiveness and Valve Performance: NYHA indications Six-minute walk tests Quality-of-life measures and cost-adequacy (center lab) Echocardiography appraisal of valve execution (center lab) Peak and mean inclinations Effective opening territory Bioprosthetic valve disgorging (esp. para-valvular ) Other: LV discharge part, MR, LV mass, proof of basic valve decay

Slide 11

Study Administration Quality of Life and Cost-Effectiveness Chairman: David J. Cohen Mid America Heart Institute, Kansas City Independent Biostatistical Core Laboratory Stuart Pocock, Duolao Wang London School of Hygiene and Tropical Medicine William N. Anderson Publications Committee Co-Chairman: Jeffrey W. Moses Lars G. Svensson Sponsor Edwards Lifesciences : Jodi J. Associated Co-Principal Investigators Martin B. Leon, Craig R. Smith Columbia University Medical Center Executive Committee Martin B. Leon, Michael Mack, D. Craig Miller, Jeffrey W. Moses, Craig R. Smith, Lars G. Svensson, E. Murat Tuzcu, John G. Webb Data & Safety Monitoring Board Chairman: Joseph P. Carrozza Tufts University School of Medicine Clinical Events Committee Chairman: John L. Petersen Duke University Medical Center Echo Core Laboratory Chairman: Pamela C. Douglas Duke University Medical Center

Slide 12

Executive Committee Lars Svensson Craig Miller Michael Mack Jeff Moses Murat Tuzcu Marty Leon John Webb Craig Smith

Slide 13

Univ. of Washington Seattle, WA Hospital Laval Quebec City, Canada Toronto Gen. Doctor's facility Toronto, Canada Mayo Clinic Rochester, MN Brigham & Women's Mass General Boston, MA Intermountain Medical Center Salt Lake City, UT Stanford University Palo Alto, CA Univ. of Penn Phila., PA Northwestern Univ. Chicago, IL Columbia University Cornell University New York, NY Cleveland Clinic Cleveland, OH Cedars-Sinai Medical Center Los Angeles, CA Washington Hosp. Focus Wash., DC Univ. of Virginia Charlottesville, VA Scripps Clinic La Jolla, CA Emory University Atlanta, GA Medical City Dallas, TX Leipzig Heart Center Leipzig, Germany Ochsner Foundation New Orleans, LA Univ. of Miami, FL Participating Study Sites St. Paul's Hospital Vancouver, Canada Evanston Hospital Barnes-Jewish Hospital St. Louis, MO St. Luke's Hospital Kansas City, MO n = 1,057 patients 26 specialist locales 22 USA, 3 Canada, 1 Germany

Slide 14

High-Risk Enrollment by Site

Slide 15

High-Risk Enrollment by Site

Slide 16

Study Devices Edwards SAPIEN THV 23 and 26 mm valves RetroFlex 22 and 24 F sheaths Ascendra 24 and 26 F sheaths

Slide 17

TAVR Transfemoral and Transapical Transfemoral

Slide 18

Inclusion Criteria • Severe AS: Echo-inferred AVA < 0.8 cm 2 ( or AVA list < 0.5 cm 2/m 2 ) and mean AVG > 40 mm Hg or pinnacle fly speed > 4.0 m/s • Cardiac Symptoms: NYHA Functional Class ≥ II High surgical hazard: Predicted danger of agent mortality ≥ 15% (dictated by site specialist and cardiologist); rule = STS score ≥ 10

Slide 19

Key Exclusion Criteria (1) Anatomic: Bicuspid or non-calcified aortic valve Aortic annulus width (reverberate estimation) < 18 mm or > 25 mm Aortic dismemberment or iliac-femoral measurements or malady blocking safe sheath addition (esp. calcification) Severe LV brokenness (LVEF < 20%) Untreated CAD requiring revascularization Severe AR or MR (> 3+) or prosthetic valve (any area)

Slide 20

Key Exclusion Criteria (2) Clinical: Serum Cr > 3.0 mg/dL or dialysis subordinate Acute MI inside 1 month Upper GI seep inside 3 months CVA or TIA inside 6 months Any heart methodology, other than BAV, inside 1 month or inside 6 months for DES Hemodynamic unsteadiness (e.g. requiring inotropic bolster)

Slide 21

Statistical Analysis Plan Primary speculation is non-mediocrity of test (TAVR) versus control (AVR) for all-cause mortality at 1 year Non-sub-par on the off chance that uneven 95% upper certainty restrain for the treatment distinction is < 7.5% ( α =0.05) Primary Endpoint: All TF and TA patients Assuming genuine 1-year mortality 32% after AVR and 29% after TAVR Intended example estimate = 650 patients for ≥ 85% power Powered Secondary Endpoint: Only TF patients Assuming genuine 1-year mortality 35% after AVR and 25% after TAVR Intended specimen measure = 450 patients for ≥ 85% power

Slide 22

Study Methodology Preliminary qualification controlled by website agents Every case inspected by online telephone call before enlistment Randomized to TF-TAVR versus AVR, or TA-TAVR versus AVR, to be dealt with inside 2 weeks Intent-to-treat (ITT) investigation for the essential and most auxiliary endpoints; characterized as the season of randomization As-treated (AT) examination for some procedural endpoints and for resound evaluations; characterized as the season of procedural anesthesia enlistment

Slide 23

Study Flow Randomized = 699 patients Transfemoral n = 492 Transapical n = 207 TF = 492 TA = 207 TAVR (244) AVR (248) TAVR (104) AVR (103) 30 Days (236) Dead = 8 Withdrawal = 0 30 Days (223) Dead = 15 Withdrawal = 10 30 Days (100) Dead = 4 Withdrawal = 0 30 Days (92) Dead = 7 Withdrawal = 4 1 Year (189) Dead = 46 Withdrawal = 1 Year (168) Dead = 47 Withdrawal = 8 1 Year (73) Dead = 26 Withdrawal = 0 LTFU = 1 Year (68) Dead = 20 Withdrawal = 3 LTFU = 1 42 Patients not regarded as doled out

Slide 24

Reasons for Non-treatment ITT = 699 patients │ AT = 657 patients NOTE: Time from randomization to treatment = TAVR 10.6 [SEM 0.7] days versus AVR 15.6 [SEM 1.1] days; P <0.001

Slide 25

Patient Characteristics (1) 5.7 6.0 Cerebrovascular ailment - %

Slide 26

Patient Characteristics (2) 0.94 43.0

Slide 27

Baseline Echocardiography

Slide 28

Procedural Outcomes - TAVR versus AVR TAVR 3 fizzled get to 2 new TEE discoveries 2 passed on Aborted system - no. (%) *Converted to transapical TAVR because of porcelain aorta

Slide 29

Procedural Outcomes - TAVR versus AVR TAVR 5 valve embolization 3 annulus measure on TEE 1 vast sigmoid septum 5 changed over to AVR 2 valve-in-valve 2 not treated Converted to AVR - no. (%) Valve embolization - no. (%) *Converted to transapical TAVR because of porcelain aorta

Slide 30

Primary Endpoint: All-Cause Mortality at 1 Year HR [95% CI] = 0.93 [0.71, 1.22] P (log rank) = 0.62 0.5 TAVR AVR 0.4 26.8 0.3 24.2 0.2 0.1 0 6 12 18 24 No. at Risk Months TAVR AVR

Slide 31

Primary Endpoint: All-Cause Mortality at 1 Year Difference -2.6% Upper 1-sided 95% CI 3.0% TAVR (N = 348) 24.2% AVR (N = 351) 26

SPONSORS